Longitudinal Dynamics of the Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Ou, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., Guo, L., Guo, R., Chen, T., Hu, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15562-9 · Cited by 3,097

Antibody responses to SARS-CoV-2 in patients with COVID-19

Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J., Wang, F., Li, D., Yang, M., Xing, L., et al. (2020) · JAMA · doi:10.1001/jama.2020.4783 · Cited by 2,298

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Duan, K., Liu, B., Li, C., Zhang, H., Yu, T., Qu, J., Zhou, M., Chen, L., Meng, S., Hu, Y., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2004168117 · Cited by 1,968

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Shi, R., Shan, C., Duan, X., Chen, Z., Liu, P., Song, J., Song, T., Bi, X., Han, C., Wu, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2381-y · Cited by 1,286

Vpr Is Required for Efficient Replication of Human Immunodeficiency Virus Type-1 in Mononuclear Phagocytes

Connor, R. I., Chen, B. K., Choe, S., & Landau, N. R. (1995) · Virology · doi:10.1006/viro.1995.1016 · Cited by 1,253

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells

Cao, Y., Su, B., Guo, X., Sun, W., Deng, Y., Bao, L., Zhu, Q., Zhang, X., Zheng, Y., Geng, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.025 · Cited by 1,188

Convalescent plasma as a potential therapy for COVID-19

Chen, L., Xiong, J., Bao, L., & Shi, Y. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30141-9 · Cited by 1,038

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237

Evolution of antibody immunity to SARS-CoV-2

Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419

Viral targets for vaccines against COVID-19

Dai, L., & Gao, G. F. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-00480-0 · Cited by 1,056

SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans

Turner, J. S., Kim, W., Kalaidina, E., Goss, C. W., Rauseo, A. M., Schmitz, A. J., Hansen, L., Haile, A., Klebert, M. K., Pusic, I., et al. (2021) · Nature · doi:10.1038/s41586-021-03647-4 · Cited by 532

Distinct Early Serological Signatures Track with SARS-CoV-2 Survival

Atyeo, C., Fischinger, S., Zohar, T., Slein, M. D., Burke, J., Loos, C., McCulloch, D. J., Newman, K. L., Wolf, C., Yu, J., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.020 · Cited by 349

Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival

Dispinseri, S., Secchi, M., Pirillo, M. F., Tolazzi, M., Borghi, M., Brigatti, C., Angelis, M. L. D., Baratella, M., Bazzigaluppi, E., Venturi, G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22958-8 · Cited by 338

A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity

Legros, V., Denolly, S., Vogrig, M., Boson, B., Siret, E., Rigaill, J., Pillet, S., Grattard, F., Gonzalo, S., Verhoeven, P. O., et al. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00588-2 · Cited by 308

The germinal centre B cell response to SARS-CoV-2

Laidlaw, B. J., & Ellebedy, A. H. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00657-1 · Cited by 268

Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection

Reynolds, C. J., Swadling, L., Gibbons, J. M., Pade, C., Jensen, M. P., Diniz, M. O., Schmidt, N. M., Butler, D. K., Amin, O. E., Bailey, S. N. L., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abf3698 · Cited by 196

The humoral response and antibodies against SARS-CoV-2 infection

Qi, H., Liu, B., Wang, X., & Zhang, L. (2022) · Nature Immunology · doi:10.1038/s41590-022-01248-5 · Cited by 195

Antibody titers against SARS-CoV-2 decline, but do not disappear for several months

Yamayoshi, S., Yasuhara, A., Ito, M., Akasaka, O., Nakamura, M., Nakachi, I., Koga, M., Mitamura, K., Yagi, K., Maeda, K., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100734 · Cited by 151

Anti-spike, Anti-nucleocapsid and Neutralizing Antibodies in SARS-CoV-2 Inpatients and Asymptomatic Individuals

Brochot, É., Demey, B., Touzé, A., Belouzard, S., Dubuisson, J., Schmit, J. L., Duverlie, G., François, C., Castelain, S., & Helle, F. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.584251 · Cited by 148

Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice

Pang, N. Y., Pang, A. S., Chow, V. T. K., & Wang, D. Y. (2021) · Military Medical Research · doi:10.1186/s40779-021-00342-3 · Cited by 146

Anti-spike antibody response to natural SARS-CoV-2 infection in the general population

Wei, J., Matthews, P. C., Stoesser, N. E., Maddox, T., Lorenzi, L., Studley, R., Bell, J. I., Newton, J. N., Farrar, J., Diamond, I. D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26479-2 · Cited by 136

Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset

Perreault, J., Tremblay, T., Fournier, M., Drouin, M., Beaudoin-Bussières, G., Prévost, J., Lewin, A., Bégin, P., Finzi, A., & Bazin, R. (2020) · Blood · doi:10.1182/blood.2020008367 · Cited by 122

Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity

Carrillo, J., Izquierdo‐Useros, N., Ávila‐Nieto, C., Pradenas, E., Clotet, B., & Blanco, J. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.10.108 · Cited by 120

Antibody Response After SARS-CoV-2 Infection and Implications for Immunity

Arkhipova-Jenkins, I., Helfand, M., Armstrong, C., Gean, E. G., Anderson, J., Paynter, R. A., & Mackey, K. (2021) · Annals of Internal Medicine · doi:10.7326/m20-7547 · Cited by 116

Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes

Pradenas, E., Trinité, B., Urrea, V., Marfil, S., Ávila‐Nieto, C., de la Concepción, M. L. R., Tarrés-Freixas, F., Pérez-Yanes, S., Rovirosa, C., Ainsua‐Enrich, E., et al. (2021) · Med · doi:10.1016/j.medj.2021.01.005 · Cited by 106

Persistence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 in Relation to Symptoms in a Nationwide Prospective Study

den Hartog, G., Vos, E. R. A., van den Hoogen, L. L., van Boven, M., Schepp, R. M., Smits, G., van Vliet, J., Woudstra, L., Wijmenga-Monsuur, A. J., van Hagen, C. C. E., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab172 · Cited by 92

Extracellular vesicles carry SARS‐CoV‐2 spike protein and serve as decoys for neutralizing antibodies

Troyer, Z., Alhusaini, N., Tabler, C. O., Sweet, T. J., Carvalho, K. I., Schlatzer, D., Carias, L. L., King, C. L., Matreyek, K. A., & Tilton, J. C. (2021) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12112 · Cited by 90

Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2

Favresse, J., Gillot, C., Chiaro, L. D., Eucher, C., Elsen, M., Eeckhoudt, S. V., David, C., Morimont, L., Dogné, J., & Douxfils, J. (2021) · Viruses · doi:10.3390/v13071364 · Cited by 85

Dysregulated Innate and Adaptive Immune Responses Discriminate Disease Severity in COVID-19

Janssen, N. A. F., Grondman, I., de Nooijer, A., Boahen, C. K., Koeken, V. A. C. M., Matzaraki, V., Kumar, V., He, X., Kox, M., Koenen, H. J. P. M., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab065 · Cited by 87

Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera

Oguntuyo, K. Y., Stevens, C. S., Hung, C.-T., Ikegame, S., Acklin, J. A., Kowdle, S., Carmichael, J. C., Chiu, H.-P., Azarm, K. D., Haas, G. D., et al. (2021) · mBio · doi:10.1128/mbio.02492-20 · Cited by 73

Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates

Boonyaratanakornkit, J. B., Morishima, C., Selke, S., Zamora, D., McGuffin, S. A., Shapiro, A. E., Campbell, V. L., McClurkan, C. L., Jing, L., Gross, R., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci144930 · Cited by 74

Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies

Kozlovskaya, L. I., Piniaeva, A. N., Ignatyev, G. M., Gordeychuk, I. V., Volok, V. P., Rogova, Y. V., Shishova, А. A., Kovpak, A. A., Ivin, Y. Y., Antonova, L. P., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1971569 · Cited by 76

A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2

Huang, Q., Ji, K., Tian, S., Wang, F., Huang, B., Tong, Z., Tan, S., Hao, J., Wang, Q., Tan, W., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21037-2 · Cited by 79

Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses

Schlickeiser, S., Schwarz, T., Steiner, S., Wittke, K., Besher, N. A., Meyer, O. G. J., Kalus, U. J., Prüß, A., Kurth, F., Zöller, T., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.628971 · Cited by 64

Dynamics of antibodies to SARS‐CoV‐2 in convalescent plasma donors

Steenhuis, M., van Mierlo, G. J., Derksen, N. I. L., Heer, P. O., Kruithof, S., Loeff, F. C., Berkhout, L. C., Linty, F., Reusken, C. B. E. M., Reimerink, J. H. J., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1285 · Cited by 63

Characterization of SARS-CoV-2-specific humoral immunity and its potential applications and therapeutic prospects

Zheng, J., Deng, Y., Zhao, Z., Mao, B., Lu, M., Lin, Y., & Huang, A. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00774-w · Cited by 65

Advances in Neutralization Assays for SARS‐CoV‐2

Lu, Y., Jin, W., Li, Q., Hu, H., Lu, J., & Chen, Z. (2021) · Scandinavian Journal of Immunology · doi:10.1111/sji.13088 · Cited by 58

Dynamics and Correlation Among Viral Positivity, Seroconversion, and Disease Severity in COVID-19

Fu, Y., Li, Y., Guo, E., He, L. J., Liu, J., Yang, B., Li, F., Wang, Z., Li, Y., Xiao, R., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m20-3337 · Cited by 56

Viral infection neutralization tests: A focus on severe acute respiratory syndrome‐coronavirus‐2 with implications for convalescent plasma therapy

Focosi, D., Maggi, F., Mazzetti, P., & Pistello, M. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2170 · Cited by 59

Antibody Duration After Infection From SARS-CoV-2 in the Texas Coronavirus Antibody Response Survey

Swartz, M. D., DeSantis, S. M., Yaseen, A. S., Brito, F. A., Valerio-Shewmaker, M. A., Messiah, S. E., León‐Novelo, L., Kohl, H. W., Pinzon-Gomez, C. L., Hao, T., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac167 · Cited by 56

Longitudinal assessment of anti-SARS-CoV-2 antibody dynamics and clinical features following convalescence from a COVID-19 infection

Gerhards, C., Thiaucourt, M., Kittel, M., Becker, C., Ast, V., Hetjens, M., Neumaier, M., & Haselmann, V. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.04.080 · Cited by 51

Persistence of Anti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for Up to 10 Months after Infection

Favresse, J., Eucher, C., Elsen, M., Gillot, C., Eeckhoudt, S. V., Dogné, J., & Douxfils, J. (2021) · Microorganisms · doi:10.3390/microorganisms9030556 · Cited by 54

The way of SARS-CoV-2 vaccine development: success and challenges

Dong, Y., Dai, T., Wang, B., Zhang, L., Zeng, L., Huang, J., Yan, H., Zhang, L., & Zhou, F. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00796-w · Cited by 53

A lymph node–targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2

Steinbuck, M. P., Seenappa, L. M., Jakubowski, A., McNeil, L. K., Haqq, C. M., & DeMuth, P. C. (2021) · Science Advances · doi:10.1126/sciadv.abe5819 · Cited by 49

Cytokine and Chemokine Levels in Coronavirus Disease 2019 Convalescent Plasma

Bonny, T. S., Patel, E. U., Zhu, X., Bloch, E. M., Grabowski, M. K., Abraham, A. G., Littlefield, K. E., Shrestha, R., Benner, S. E., Laeyendecker, O. B., et al. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa574 · Cited by 52

SARS-CoV-2 Proteome-Wide Analysis Revealed Significant Epitope Signatures in COVID-19 Patients

Schwarz, T., Heiß, K., Mahendran, Y., Casilag, F., Kurth, F., Sander, L. E., Wendtner, C., Hoechstetter, M. A., Müller, M. A., Sekul, R., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.629185 · Cited by 45

Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities

Noval, M. G., Kaczmarek, M. E., Koide, A., Rodriguez-Rodriguez, B. A., Louie, P., Tada, T., Hattori, T., Panchenko, T., Romero, L. A., Teng, K. W., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-84913-3 · Cited by 53

Neutralizing antibody responses following natural SARS-CoV-2 infection: Dynamics and correlation with commercial serologic tests.

Montesinos, I., Dahma, H., Wolff, F., Dauby, N., Delaunoy, S., Wuyts, M., Detemmerman, C., Duterme, C., Vandenberg, O., Martin, C., et al. (2021) · Journal of Clinical Virology · doi:10.1016/j.jcv.2021.104988 · Cited by 44

Intranasal administration of a recombinant RBD vaccine induces long-term immunity against Omicron-included SARS-CoV-2 variants

Hong, L., Alu, A., Yang, J., Ren, W., He, C., Lan, T., He, X., Yang, L., Li, J., Wang, Z., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01002-1 · Cited by 43

Neutralizing antibodies against SARS-CoV-2: current understanding, challenge and perspective

Huang, Y., Sun, H., Yu, H. J., Li, S., Zheng, Q., & Xia, N. (2020) · Antibody Therapeutics · doi:10.1093/abt/tbaa028 · Cited by 40

Sample pooling strategies for SARS-CoV-2 detection

Lаgopati, N., Tsioli, P., Mourkioti, I., Polyzou, A., Papaspyropoulos, A., Zafiropoulos, A., Evangelou, K., Sourvinos, G., & Gorgoulis, V. G. (2020) · Journal of Virological Methods · doi:10.1016/j.jviromet.2020.114044 · Cited by 40

Immune memory in convalescent patients with asymptomatic or mild COVID-19

Long, Q., Jia, Y., Wang, X., Deng, H., Cao, X., Yuan, J., Fang, L., Cheng, X.-R., Luo, C., He, A.-R., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00250-9 · Cited by 41

Evaluation of a Surrogate Enzyme-Linked Immunosorbent Assay–Based Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) cPass Neutralization Antibody Detection Assay and Correlation With Immunoglobulin G Commercial Serology Assays

Nandakumar, V., Profaizer, T., Lozier, B. K., Elgort, M., Larragoite, E. T., Williams, E. S. C. P., Solis‐Leal, A., Lopez, J., Berges, B. K., Planelles, V., et al. (2021) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2021-0213-sa · Cited by 38

Initial immune response after exposure to Mycobacterium tuberculosis or to SARS-COV-2: similarities and differences

Aiello, A., Fard, S. N., & Goletti, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1244556 · Cited by 38

Nationwide Seroprevalence of SARS-CoV-2 in Saudi Arabia

Alharbi, N. K., Alghnam, S. A., Algaissi, A. A., Albalawi, H., Alenazi, M. W., Albargawi, A. M., Alharbi, A. G., Alhazmi, A., Qarni, A. A. A., Alfarhan, A., et al. (2021) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.04.006 · Cited by 40

The intersection of COVID-19 and autoimmunity: What is our current understanding?

Winchester, N., Calabrese, C. M., & Calabrese, L. H. (2021) · Pathogens and Immunity · doi:10.20411/pai.v6i1.417 · Cited by 40

A SARS‐CoV‐2 Neutralization Assay Using Single Molecule Arrays

Gilboa, T., Cohen, L., Cheng, C., Lazarovits, R., Uwamanzu‐Nna, A., Han, I., Griswold, K., Barry, N., Thompson, D. B., Kohman, R. E., et al. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202110702 · Cited by 34

COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review

Simnani, F. Z., Singh, D., & Kaur, R. (2021) · 3 Biotech · doi:10.1007/s13205-021-03076-0 · Cited by 35

Clinical Performance of a Standardized Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Interferon-γ Release Assay for Simple Detection of T-Cell Responses After Infection or Vaccination

Fernández‐González, M., Agulló, V., Padilla, S., García, J. A., García‐Abellán, J., Botella, Á., Mascarell, P., Ruiz‐García, M., Masiá, M., & Gutiérrez, F. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1021 · Cited by 34

Heterogenous humoral and cellular immune responses with distinct trajectories post-SARS-CoV-2 infection in a population-based cohort

Menges, D., Zens, K. D., Ballouz, T., Caduff, N., Llanas-Cornejo, D., Aschmann, H. E., Domenghino, A., Pellaton, C., Perreau, M., Fenwick, C. W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32573-w · Cited by 32

Plasma cytokines in patients with COVID-19 during acute phase of the disease and following complete recovery

Arsentieva, N. A., Liubimova, N. E., Batsunov, O. K., Korobova, Z. R., Stanevich, O. V., Lebedeva, A. A., Vorobyov, E. A., Vorobyeva, S. V., Куликов, А. Н., Lioznov, D. A., et al. (2021) · Medical Immunology (Russia) · doi:10.15789/1563-0625-pci-2312 · Cited by 33

A rapid simple point-of-care assay for the detection of SARS-CoV-2 neutralizing antibodies

Kongsuphol, P., Jia, H., Cheng, H. L., Gu, Y., Shunmuganathan, B. D. O., Chen, M. W., Lim, S. M., Ng, S. Y., Tambyah, P. A., Nasir, H., et al. (2021) · Communications Medicine · doi:10.1038/s43856-021-00045-9 · Cited by 33

Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset

Sasisekharan, V., Pentakota, N., Jayaraman, A., Tharakaraman, K., Wogan, G. N., & Narayanasami, U. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2021615118 · Cited by 30

Dynamic changes and prevalence of SARS-CoV-2 IgG/IgM antibodies: Analysis of multiple factors

Luo, C., Liu, M., Li, Q., Zheng, X., Ai, W., Gong, F., Fan, J., Liu, S., Wang, X., & Luo, J. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.04.078 · Cited by 31

SARS -CoV-2 T-cell immunity to variants of concern following vaccinationPreprint

Gallagher, K., Leick, M. B., Larson, R. C., Berger, T. R., Katsis, K., Yam, J. Y., Brini, G., Grauwet, K., MGH COVID-19 Collection & Processing Team, & Maus, M. V. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.03.442455 · Cited by 32

Convalescent Plasma-Mediated Resolution of Covid-19 in Humoral Immunodeficiency

Honjo, K., Russell, R. M., Li, R., Liu, W., Stoltz, R., Tabengwa, E. M., Hua, Y., Prichard, L. E., Kornbrust, A., Sterrett, S., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100164 · Cited by 26

The role of pseudotype neutralization assays in understanding SARS CoV-2

Cantoni, D. M., Neto, M. M., & Temperton, N. J. (2021) · Oxford Open Immunology · doi:10.1093/oxfimm/iqab005 · Cited by 27

A SARS-CoV-2 Label-Free Surrogate Virus Neutralization Test and a Longitudinal Study of Antibody Characteristics in COVID-19 Patients

Luo, Y. R., Yun, C., Chakraborty, I., Wu, A. H. B., & Lynch, K. L. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00193-21 · Cited by 24

Longitudinal Assessment of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Immune Responses for Six Months Based on the Clinical Severity of Coronavirus Disease 2019

Noh, J. Y., Kwak, J.-E., Yang, J., Hwang, S. Y., Yoon, J. G., Seong, H., Hyun, H., Lim, C. S., Yoon, S., Ryou, J., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab124 · Cited by 24

Previous viral symptoms and individual mothers influenced the leveled duration of human milk antibodies cross-reactive to S1 and S2 subunits from SARS-CoV-2, HCoV-229E, and HCoV-OC43

Demers‐Mathieu, V., DaPra, C., Mathijssen, G. B., & Medo, E. T. (2021) · Journal of Perinatology · doi:10.1038/s41372-021-01001-0 · Cited by 26

Immune profiling of COVID-19: preliminary findings and implications for the pandemic

Maecker, H. T. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002550 · Cited by 26

Prevalence of neutralising antibodies against SARS-CoV-2 in acute infection and convalescence: A systematic review and meta-analysis

Savage, H. R., Santos, V. S., Edwards, T., Giorgi, E., Krishna, S., Planche, T., Staines, H. M., Fitchett, J. R. A., Kirwan, D. E., Cubas-Atienzar, A. I., et al. (2021) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0009551 · Cited by 24

Early and long term antibody kinetics of asymptomatic and mild disease COVID-19 patients

Efrati, S., Catalogna, M., Hamed, R. A., Hadanny, A., Bar‐Chaim, A., Benveniste‐Levkovitz, P., Strugo, R., & Levtzion‐Korach, O. (2021) · Scientific Reports · doi:10.1038/s41598-021-93175-y · Cited by 25

Maternal Antibody Response and Transplacental Transfer Following Severe Acute Respiratory Syndrome Coronavirus 2 Infection or Vaccination in Pregnancy

Otero, S., Miller, E. S., Sunderraj, A., Shanes, E. D., Sakowicz, A., Goldstein, J. A., & Mithal, L. B. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac793 · Cited by 25

Cellular metabolic basis of altered immunity in the lungs of patients with COVID-19

Li, S., Zhao, F., Ye, J., Li, K., Wang, Q., Du, Z., Yue, Q., Wang, S., Wu, Q., & Chen, H. (2022) · Medical Microbiology and Immunology · doi:10.1007/s00430-021-00727-0 · Cited by 25

Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination

Underwood, A. P., Sølund, C. S., Fernandez-Antunez, C., Villadsen, S. L., Mikkelsen, L. S., Fahnøe, U., Bollerup, S., Winckelmann, A. A., Schneider, U. V., Binderup, A., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104475 · Cited by 21

More Than Just Gene Therapy Vectors: Lentiviral Vector Pseudotypes for Serological Investigation

Toon, K., Bentley, E. M., & Mattiuzzo, G. (2021) · Viruses · doi:10.3390/v13020217 · Cited by 23

A longitudinal study of convalescent plasma ( CCP ) donors and correlation of ABO group, initial neutralizing antibodies ( nAb ), and body mass index ( BMI ) with nAb and anti‐nucleocapsid ( NP ) SARS‐CoV ‐2 antibody kinetics: Proposals for better quality of CCP collections

Wendel, S., Fontão‐Wendel, R., Fachini, R. M., Candelaria, G. D. T. P., Scuracchio, P., Achkar, R., Brito, M., Reis, L. F. L., Camargo, A. A., Amano, M. T., et al. (2021) · Transfusion · doi:10.1111/trf.16323 · Cited by 21

Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study

Karuna, S., Li, S. S., Grant, S., Walsh, S. R., Frank, I., Casapía, M., Trahey, M., Hyrien, O., Fisher, L. H., Miner, M. D., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003868 · Cited by 21

Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19

Underwood, A. P., Sølund, C. S., Fernandez-Antunez, C., Villadsen, S. L., Winckelmann, A. A., Bollerup, S., Mikkelsen, L. S., Sørensen, A.-L., Feng, S., Fahnøe, U., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103519 · Cited by 23

Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China

Feng, X., Yin, J., Zhang, J., Hu, Y., Ouyang, Y., Qiao, S., Zhao, H., Zhang, T., Li, X., Zhang, L., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.614436 · Cited by 22

Genomic, immunological, and clinical analysis of COVID‐19 vaccine breakthrough infections in Beijing, China

Tian, D., Song, Y., Zhang, M., Pan, Y., Ge, Z., Zhang, Y., Ren, X., Wen, J., Xu, Y., Guo, H., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27636 · Cited by 18

Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2

Sun, Y., Zhou, J.-J., Zhu, H.-P., Fang, X., Zhao, W., Lu, H.-J., Wang, Z., Chen, S., Yao, P.-P., Jiang, J.-M., et al. (2021) · Viruses · doi:10.3390/v13101936 · Cited by 19

Robust Neutralizing Antibody Levels Detected after Either SARS-CoV-2 Vaccination or One Year after Infection

Glöckner, S., Hornung, F., Baier, M., Weis, S., Pletz, M. W., Deinhardt‐Emmer, S., Löffler, B., & the CoNAN Study Group (2021) · Viruses · doi:10.3390/v13102003 · Cited by 19

Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection

Kučinskaitė-Kodzė, I., Simanavičius, M., Šimaitis, A., & Žvirblienė, A. (2021) · Viruses · doi:10.3390/v13112313 · Cited by 19

Canadian society of clinical chemists (CSCC) interim consensus guidance for testing and reporting of SARS-CoV-2 serology

Bailey, D., Konforte, D., Barakauskas, V., Yip, P. S. F., Kulasingam, V., Hassan, M. A. E., Beach, L. A., Blasutig, I. M., Catomeris, P., Dooley, K., et al. (2020) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2020.09.005 · Cited by 19

SARS-CoV-2 virus: Vaccines in development

Huang, Q., & Yan, J. (2021) · Fundamental Research · doi:10.1016/j.fmre.2021.01.009 · Cited by 18

Pathophysiology of acute respiratory syndrome coronavirus 2 infection: a systematic literature review to inform EULAR points to consider

Najm, A., Alunno, A., Mariette, X., Terrier, B., Marco, G. D., Emmel, J., Mason, L., McGonagle, D., & Machado, P. (2021) · RMD Open · doi:10.1136/rmdopen-2020-001549 · Cited by 17

Persistence of humoral response upon SARS‐CoV‐2 infection

Knies, A., Ladage, D., Braun, R. J., Kimpel, J., & Schneider, M. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2272 · Cited by 17

Long-term kinetics of anti-SARS-CoV-2 antibodies in a cohort of 197 hospitalized and non-hospitalized COVID-19 patients

Favresse, J., Elsen, M., Eucher, C., Laffineur, K., Eeckhoudt, S. V., Nicolas, J., Gillot, C., Dogné, J.-M., & Douxfils, J. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2020-1736 · Cited by 16

Reasons of Vaccine Hesitancy among Pakistanis with Available COVID-19 Vaccine: The Next Challenge in the Fight against COVID-19

Rizwan, W., Rana, M. N., Bukhari, M. H., Mushtaq, A., & Sadiq, M. (2021) · Natural Science · doi:10.4236/ns.2021.136018 · Cited by 17

Rapid detection of neutralizing antibodies to SARS-CoV-2 variants in post-vaccination sera

Miyakawa, K., Jeremiah, S. S., Kato, H., Yamaoka, Y., Go, H., Yajima, S., Shimada, T., Mihara, T., Goto, A., Yamanaka, T., et al. (2021) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjab050 · Cited by 17

Detection and Quantification of Antibody to SARS-CoV-2 Receptor Binding Domain Provides Enhanced Sensitivity, Specificity and Utility

Rosadas, C., Khan, M., Parker, E. L., Marchesin, F., Katsanovskaja, K., Sureda-Vives, M., Fernández, N., Randell, P. A., Harvey, R., Lilley, A., et al. (2020) · Journal of Virological Methods · doi:10.1016/j.jviromet.2022.114475 · Cited by 17

Humoral and Cellular Response of Transplant Recipients to a Third Dose of mRNA SARS-CoV-2 Vaccine: A Systematic Review and Meta-analysis

Bailey, A., Maganti, H., Cheng, W., Shorr, R., Buchan, C., & Allan, D. (2022) · Transplantation · doi:10.1097/tp.0000000000004386 · Cited by 12

Plaque Reduction Neutralization Test (PRNT) Accuracy in Evaluating Humoral Immune Response to SARS-CoV-2

Horbach, I. S., Azevedo, A. D. S., Schwarcz, W. D., Alves, N. D. S., Dias, B. D. M., Setatino, B. P., Moura, L. D. C., de Souza, A. F., Denani, C. B., da Silva, S. A., et al. (2024) · Diseases · doi:10.3390/diseases12010029 · Cited by 17

Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France

Carrat, F., Lapidus, N., Ninove, L., Blanché, H., Rahib, D., Villarroel, P. M. S., Touvier, M., Severi, G., Zins, M., Deleuze, J., et al. (2021) · Infection · doi:10.1007/s15010-021-01731-5 · Cited by 15

Persistent Antibody Responses Up to 18 Months After Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Choe, P. G., Hong, J., Park, J., Chang, E., Kang, C. K., Kim, N. J., Lee, C. H., Park, W. B., & Oh, M. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac099 · Cited by 16

Changes in the humoral immunity response in SARS-CoV-2 convalescent patients over 8 months

Peng, P., Hu, J., Deng, H., Liu, B., Fang, L., Wang, K., Tang, N., & Huang, A. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00605-4 · Cited by 15

How can we interpret SARS-CoV-2 antibody test results?

Føns, S., & Krogfelt, K. A. (2020) · Pathogens and Disease · doi:10.1093/femspd/ftaa069 · Cited by 17

A trend of dropping anti‐SARS‐CoV‐2 plaque reduction neutralization test titers over time in Canadian convalescent plasma donors

Drews, S. J., Devine, D. V., McManus, J., Mendoza, E. J., Manguiat, K., Wood, H., Girardin, R. C., Dupuis, A. P., McDonough, K. A., & DREBOT, M. A. (2021) · Transfusion · doi:10.1111/trf.16364 · Cited by 15

Evaluation of 18 commercial serological assays for the detection of antibodies against SARS-CoV-2 in paired serum samples

Hanssen, D. A. T., Slaats, M., Mulder, M., Savelkoul, P. H. M., & van Loo, I. H. M. (2021) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-021-04220-7 · Cited by 15

Convalescent Plasma Therapy for Coronavirus Disease 2019

Choi, J. Y. (2020) · Infection and Chemotherapy · doi:10.3947/ic.2020.52.3.307 · Cited by 15

TOP-Plus Is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability

Racine‐Brzostek, S., Karbaschi, M., Gaebler, C., Klasse, P. J., Yee, J. K., Caskey, M. F., Yang, H. S., Hao, Y., Sukhu, A. C., Rand, S., et al. (2021) · Clinical Chemistry · doi:10.1093/clinchem/hvab069 · Cited by 12

Dynamic observation of SARS‐CoV‐2 IgM, IgG, and neutralizing antibodies in the development of population immunity through COVID‐19 vaccination

Jiang, R., Dou, X., Li, M., Wang, E., Hu, J., Xiong, D., & Zhang, X. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24325 · Cited by 11

Kinetics of neutralizing antibodies against SARS-CoV-2 infection according to sex, age, and disease severity

Kim, Y., Bae, J., Kwon, K. T., Chang, H., Lee, W. K., Park, H., Kim, J., Choi, I., Park, M., & Kim, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-17605-1 · Cited by 12

Multiplex assessment of SARS-CoV-2 antibodies improves assay sensitivity and correlation with neutralizing antibodies

Cook, N., Xu, L., Hegazy, S. E., Wheeler, B. J., Anderson, A., Critelli, N., Yost, M., McElroy, A. K., Shurin, M. R., & Wheeler, S. (2021) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2021.08.006 · Cited by 11

Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Crawford, K. H. D., Dingens, A. S., Eguia, R., Wolf, C. R., Wilcox, N., Logue, J. K., Shuey, K., Casto, A. M., Fiala, B., Wrenn, S., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa618 · Cited by 265

Dynamics of neutralizing antibody responses to SARS-CoV-2 in patients with COVID-19: an observational study

Xu, X. P., Nie, S., Wang, Y., Long, Q., Zhu, H., Zhang, X., Sun, J., Zeng, Q., Zhao, J., Liu, L., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00611-6 · Cited by 28

Kinetic Characteristics of Neutralizing Antibody Responses Vary among Patients with COVID-19.

Li, L. H., Tu, H. W., Liang, D., Wen, C. Y., Li, A. A., Lin, W. Y., Hu, K. Q., Hong, W. S., Li, Y. P., Su, J., et al. (2021) · PubMed Central · doi:10.3967/bes2021.133 · Cited by 1

The changing dynamics of neutralizing antibody response within 10 months of SARS‐CoV‐2 infections

Baştuğ, A., Bodur, H., Aydos, Ö., Filazi, N., Öksüz, E., & Özkul, A. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27544 · Cited by 2

SARS‐CoV‐2 neutralizing antibodies decline over one year and patients with severe COVID‐19 pneumonia display a unique cytokine profile

Vacharathit, V., Srichatrapimuk, S., Manopwisedjaroen, S., Kirdlarp, S., Srisaowakarn, C., Setthaudom, C., Inrueangsri, N., Pisitkun, P., Kunakorn, M., Hongeng, S., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.09.021 · Cited by 22